Loading...
•
Jun 30, 2021
Krystal Biotech Q2 2021 Earnings Report
Reported financial results for the second quarter and provided update on operational progress.
Key Takeaways
Krystal Biotech reported financial results for the second quarter ending June 30, 2021. The company is advancing three clinical stage programs and made significant headway on the construction of its 2nd GMP manufacturing facility. Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa is on track for 4Q21. Initiation of Phase 1 study of inhaled KB407 for the treatment of cystic fibrosis is expected in 3Q21.
Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (“DEB”) on track for 4Q21.
Initiation of Phase 1 study of inhaled KB407 for the treatment of cystic fibrosis expected in 3Q21.
Jeune Aesthetics, Inc. initiated dosing in the efficacy cohort of the PEARL-1 study of intradermal KB301 for aesthetic skin conditions
Cash, cash equivalents and marketable securities of $389.1 million on June 30, 2021
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...